To evaluate the efficacy and safety of 1064 nm picosecond laser combined with 1565 nm non-ablative fractional laser for the treatment of periorbital rejuvenation.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600128518

Enrollment

Unknown

Registered

2026-07-21

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periorbital aging is characterized by multi-layered degenerative alterations, including deepening rhytides, hyperpigmentation (periorbital hyperpigmentation), rough texture, loss of elasticity, and ptosis, and represents the earliest facial region to exhibit aging stigmata. Given the distinctive anatomical features of the periorbital skin, monotherapy with a single laser modality is often inadequa

Interventions

Control side:Single treatment (Full face ultra-picosecond)

Intervention side:Combined treatment (full face ultra-picosecond + unilateral periorbital non-ablative fractional laser)

Eligibility

Sex/Gender

All

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age: 25 to 55 years old, gender not limited. 2. The bilateral periorbital aging conditions are basically symmetrical, and there are obvious signs of periorbital aging (such as fine lines on the lower eyelid, pigmentation, skin laxity, etc.); 3. Fitzpatrick skin Classification types II-IV; 4. Informed consent, voluntary enrollment and signing of the informed consent form, willing to cooperate with follow-up and photography.

Exclusion criteria

Exclusion criteria: 1. Patients with keloid tendency. 2. Those with active infection or skin disease in the treatment area. 3. Those who have received periorbital area-related treatments (such as laser, radiofrequency, injection, surgery) within the past 6 months. 4. Pregnant or breastfeeding women. 5. Those with photosensitivity disorders, immune system diseases, or coagulation disorders. 6. Those who have long-term use of photosensitive medications or anticoagulant drugs.

Design outcomes

Primary

Measure	Time frame
The percentage of periorbital wrinkles detected by the VISIA skin analyzer;The proportion of subjects with a score of +2 on the 9-point Global Beauty Improvement Scale (GAIS);	—

Secondary

Measure	Time frame
The changes in the percentage of spots and textures detected by VISIA at each time point;The changes in moisture and elasticity detected by the skin tester at various time points;The satisfaction of patients;The degree of pain after each treatment (VAS score);Adverse reactions (erythema, edema, pigmentation, blisters, infection, etc.);	—

Countries

China

Contacts

Public ContactWang Yanting

Xi'an International Medical Center Hospital

324007489@qq.com+86 29 89811884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026